Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Characterization of organoid cultured human breast cancer.

Goldhammer N, Kim J, Timmermans-Wielenga V, Petersen OW.

Breast Cancer Res. 2019 Dec 11;21(1):141. doi: 10.1186/s13058-019-1233-x.

PMID:
31829259
2.

A CD146 FACS Protocol Enriches for Luminal Keratin 14/19 Double Positive Human Breast Progenitors.

Gerdur Ísberg Ó, Kim J, Fridriksdottir AJ, Morsing M, Timmermans-Wielenga V, Rønnov-Jessen L, Petersen OW, Villadsen R.

Sci Rep. 2019 Oct 16;9(1):14843. doi: 10.1038/s41598-019-50903-9.

3.

Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics.

Espinoza JA, Jabeen S, Batra R, Papaleo E, Haakensen V, Timmermans Wielenga V, Møller Talman ML, Brunner N, Børresen-Dale AL, Gromov P, Helland Å, Kristensen VN, Gromova I.

Oncoimmunology. 2016 Oct 24;5(12):e1248015. doi: 10.1080/2162402X.2016.1248015. eCollection 2016.

4.

Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients.

Liu NQ, De Marchi T, Timmermans A, Trapman-Jansen AM, Foekens R, Look MP, Smid M, van Deurzen CH, Span PN, Sweep FC, Brask JB, Timmermans-Wielenga V, Foekens JA, Martens JW, Umar A.

Sci Rep. 2016 Aug 25;6:32027. doi: 10.1038/srep32027.

5.

High-density SNP arrays improve detection of HER2 amplification and polyploidy in breast tumors.

Hansen TV, Vikesaa J, Buhl SS, Rossing HH, Timmermans-Wielenga V, Nielsen FC.

BMC Cancer. 2015 Feb 6;15:35. doi: 10.1186/s12885-015-1035-1.

6.

FABP7 and HMGCS2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast.

Gromov P, Espinoza JA, Talman ML, Honma N, Kroman N, Timmermans Wielenga V, Moreira JM, Gromova I.

PLoS One. 2014 Nov 12;9(11):e112024. doi: 10.1371/journal.pone.0112024. eCollection 2014.

7.

Ferritin heavy chain in triple negative breast cancer: a favorable prognostic marker that relates to a cluster of differentiation 8 positive (CD8+) effector T-cell response.

Liu NQ, De Marchi T, Timmermans AM, Beekhof R, Trapman-Jansen AM, Foekens R, Look MP, van Deurzen CH, Span PN, Sweep FC, Brask JB, Timmermans-Wielenga V, Debets R, Martens JW, Foekens JA, Umar A.

Mol Cell Proteomics. 2014 Jul;13(7):1814-27. doi: 10.1074/mcp.M113.037176. Epub 2014 Apr 17.

8.

A marker of endocrine receptor-positive cells, CEACAM6, is shared by two major classes of breast cancer: luminal and HER2-enriched.

Balk-Møller E, Kim J, Hopkinson B, Timmermans-Wielenga V, Petersen OW, Villadsen R.

Am J Pathol. 2014 Apr;184(4):1198-208. doi: 10.1016/j.ajpath.2013.12.013.

PMID:
24655379
9.

Tumor interstitial fluid - a treasure trove of cancer biomarkers.

Gromov P, Gromova I, Olsen CJ, Timmermans-Wielenga V, Talman ML, Serizawa RR, Moreira JM.

Biochim Biophys Acta. 2013 Nov;1834(11):2259-70. doi: 10.1016/j.bbapap.2013.01.013. Epub 2013 Feb 14. Review.

PMID:
23416532
10.

Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.

Cabezón T, Gromova I, Gromov P, Serizawa R, Timmermans Wielenga V, Kroman N, Celis JE, Moreira JM.

Mol Cell Proteomics. 2013 Feb;12(2):381-94. doi: 10.1074/mcp.M112.019786. Epub 2012 Nov 20.

11.

Cryopreservation of ovarian tissue for fertility preservation: no evidence of malignant cell contamination in ovarian tissue from patients with breast cancer.

Rosendahl M, Timmermans Wielenga V, Nedergaard L, Kristensen SG, Ernst E, Rasmussen PE, Anderson M, Schmidt KT, Andersen CY.

Fertil Steril. 2011 May;95(6):2158-61. doi: 10.1016/j.fertnstert.2010.12.019. Epub 2011 Jan 12.

PMID:
21227414
12.

Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.

Moreira JM, Cabezón T, Gromova I, Gromov P, Timmermans-Wielenga V, Machado I, Llombart-Bosch A, Kroman N, Rank F, Celis JE.

Mol Oncol. 2010 Dec;4(6):539-61. doi: 10.1016/j.molonc.2010.09.005. Epub 2010 Oct 8.

13.

Proteomic profiling of mammary carcinomas identifies C7orf24, a gamma-glutamyl cyclotransferase, as a potential cancer biomarker.

Gromov P, Gromova I, Friis E, Timmermans-Wielenga V, Rank F, Simon R, Sauter G, Moreira JM.

J Proteome Res. 2010 Aug 6;9(8):3941-53. doi: 10.1021/pr100160u.

PMID:
20527979
14.

Epithelial-stromal interaction 1 (EPSTI1) substitutes for peritumoral fibroblasts in the tumor microenvironment.

de Neergaard M, Kim J, Villadsen R, Fridriksdottir AJ, Rank F, Timmermans-Wielenga V, Langerød A, Børresen-Dale AL, Petersen OW, Rønnov-Jessen L.

Am J Pathol. 2010 Mar;176(3):1229-40. doi: 10.2353/ajpath.2010.090648. Epub 2010 Feb 4.

15.

Primary cardiac tumors: a clinicopathologic evaluation of four cases.

Winther C, Timmermans-Wielenga V, Daugaard S, Mortensen SA, Sander K, Andersen CB.

Cardiovasc Pathol. 2011 Jan-Feb;20(1):63-7. doi: 10.1016/j.carpath.2009.11.004. Epub 2010 Jan 8.

PMID:
20060324
16.

Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast.

Gromov P, Gromova I, Bunkenborg J, Cabezon T, Moreira JM, Timmermans-Wielenga V, Roepstorff P, Rank F, Celis JE.

Mol Oncol. 2010 Feb;4(1):65-89. doi: 10.1016/j.molonc.2009.11.003. Epub 2009 Nov 23.

17.

DNA copy number aberrations in breast cancer by array comparative genomic hybridization.

Li J, Wang K, Li S, Timmermans-Wielenga V, Rank F, Wiuf C, Zhang X, Yang H, Bolund L.

Genomics Proteomics Bioinformatics. 2009 Jun;7(1-2):13-24. doi: 10.1016/S1672-0229(08)60029-7.

18.

A high frequent BRCA1 founder mutation identified in the Greenlandic population.

Harboe TL, Eiberg H, Kern P, Ejlertsen B, Nedergaard L, Timmermans-Wielenga V, Nielsen IM, Bisgaard ML.

Fam Cancer. 2009;8(4):413-9. doi: 10.1007/s10689-009-9257-5. Epub 2009 Jun 7.

PMID:
19504351
19.

Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort.

Celis JE, Cabezón T, Moreira JM, Gromov P, Gromova I, Timmermans-Wielenga V, Iwase T, Akiyama F, Honma N, Rank F.

Mol Oncol. 2009 Jun;3(3):220-37. doi: 10.1016/j.molonc.2009.01.005. Epub 2009 Feb 3.

20.

A single lysis solution for the analysis of tissue samples by different proteomic technologies.

Gromov P, Celis JE, Gromova I, Rank F, Timmermans-Wielenga V, Moreira JM.

Mol Oncol. 2008 Dec;2(4):368-79. doi: 10.1016/j.molonc.2008.09.003. Epub 2008 Oct 2.

21.

Omics-based profiling of carcinoma of the breast and matched regional lymph node metastasis.

Li J, Gromov P, Gromova I, Moreira JM, Timmermans-Wielenga V, Rank F, Wang K, Li S, Li H, Wiuf C, Yang H, Zhang X, Bolund L, Celis JE.

Proteomics. 2008 Dec;8(23-24):5038-52. doi: 10.1002/pmic.200800303.

PMID:
19003862
22.

15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma.

Celis JE, Gromov P, Cabezón T, Moreira JM, Friis E, Jirström K, Llombart-Bosch A, Timmermans-Wielenga V, Rank F, Gromova I.

Mol Cell Proteomics. 2008 Oct;7(10):1795-809. doi: 10.1074/mcp.R800011-MCP200. Epub 2008 Jul 16.

23.

A common Greenlandic Inuit BRCA1 RING domain founder mutation.

Hansen TV, Ejlertsen B, Albrechtsen A, Bergsten E, Bjerregaard P, Hansen T, Myrhøj T, Nielsen PB, Timmermans-Wielenga V, Andersen MK, Jønson L, Nielsen FC.

Breast Cancer Res Treat. 2009 May;115(1):69-76. doi: 10.1007/s10549-008-0060-z. Epub 2008 May 26.

PMID:
18500671
24.

Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease.

Celis JE, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans-Wielenga V, Rank F, Moreira JM.

Mol Oncol. 2007 Dec;1(3):321-49. doi: 10.1016/j.molonc.2007.09.004. Epub 2007 Sep 25.

Supplemental Content

Loading ...
Support Center